NCT06943937View on ClinicalTrials.gov

A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

April 25, 2026

Study Completion Date

April 25, 2027

Conditions
Lupus Nephritis (LN)Immune Thrombocytopenia (ITP)
Interventions
DRUG

YTS109 cell injection

Subjects will receive YTS109 Cell Injection(1E6 STAR+T cell/kg or 2E6 STAR+T cell/kg) once in this study.

Trial Locations (1)

102206

RECRUITING

Beijing GoBroad Hospital, Beijing

All Listed Sponsors
lead

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY